Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion type Assertion NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_head.
- NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion description "[Our results suggest that lymphangiogenic markers, such as VEGF-D and VEGFR-2 and VEGFR-3, may be better than angiogenic markers as targets of therapeutic intervention in advanced-stage prostate disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_provenance.
- NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion evidence source_evidence_literature NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_provenance.
- NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion SIO_000772 15701844 NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_provenance.
- NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion wasDerivedFrom befree-20140225 NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_provenance.
- NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_assertion wasGeneratedBy ECO_0000203 NP802257.RA0rX6bbe4pMr2PZQ10gyZT2nLer2JKnM2bJvWQA_UPYA130_provenance.